NIK/MAP3K14 in hepatocytes orchestrates NASH to hepatocellular carcinoma progression via JAK2/STAT5 inhibition

• Main Authors: Anna Juliane Vesting (Author), Alexander Jais (Author), Paul Klemm (Author), Lukas Steuernagel (Author), Peter Wienand (Author), Morten Fog-Tonnesen (Author), Henning Hvid (Author), Anna-Lena Schumacher (Author), Christian Kukat (Author), Hendrik Nolte (Author), Theodoros Georgomanolis (Author), Janine Altmüller (Author), Manolis Pasparakis (Author), Andreas Schmidt (Author), Marcus Krüger (Author), Marc Schmidt Supprian (Author), Ari Waisman (Author), Beate Katharina Straub (Author), Nathanael Raschzok (Author), Michel Bernier (Author), Andreas L. Birkenfeld (Author), Nadine Hövelmeyer (Author), Jens C. Brüning (Author), F. Thomas Wunderlich (Author)
• Format: Book
• Published: Elsevier, 2022-12-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Objective: Nonalcoholic fatty liver disease (NAFLD) ranges from steatosis to nonalcoholic steatohepatitis (NASH), which often progresses to hepatocellular carcinoma (HCC) through a largely undefined mechanism. NASH and HCC depend on inflammatory signaling, whose master regulator is the NFκB transcri...